Group items tagged

The Royal Pharmaceutical Society (RPS) in collaboration with Health Education England's Centre for Advancing Practice and the Centre for Pharmacy Post Graduate Education (CPPE) will provide a pharmacy-specific professional development pathway for advanced pharmacist practice. Successful completion of the pathway, assured through the RPS Core Advanced Pharmacist Curriculum assessment, will result in pharmacists being recognised by RPS as an advanced pharmacist, along with the awarding of HEE's Centre for Advancing Practice's 'Advanced' digital badge, demonstrating the quality assurance of their advanced practice preparation to patients, families, carers, and other healthcare professionals. The first participants in a fully funded, supported e-portfolio pathway to recognise advanced pharmacist practice in England will get underway in March 2023 This new programme is an important step in creating a clear postgraduate career structure for pharmacists in England. The innovative approach provides funding from HEE's Centre for Advancing Practice in 2023-24 for 300 pharmacists in England who are near to, or already practicing at, an advanced level, to enable them to receive supervision and support in building their RPS Core Advanced e-Portfolio from CPPE's pharmacy education supervisors.

Computer Science Tuesday, April 25, 2023 Computer hardware Computer hardware is the physical components that make up a computer system. It includes everything from the central processing unit (CPU) to the monitor, keyboard, and mouse. Understanding the different types of hardware and how they work together is essential for anyone who works with computers. In this article, we will explore the various components of computer hardware, including internal and external components, and the peripherals that connect to them. We will also discuss the importance of hardware maintenance, the latest advancements in computer technology, and factors to consider when choosing the right hardware for your needs. Whether you are a computer technician, a gamer, or simply someone who uses a computer for everyday tasks, this article will help you better understand the world of computer hardware. Introduction to Computer Hardware Computer hardware refers to the physical components that make up a computer system. It includes everything from the processor and memory to input/output devices such as the keyboard and monitor. In this article, we will explore the different types of computer hardware and their functions. What is Computer Hardware Computer hardware refers to the physical components of a computer system. It includes all the components that can be touched, seen, and used to interact with a computer, such as the monitor, keyboard, and mouse. Hardware is different from computer software, which refers to the programs and applications that run on a computer system. History of Computer Hardware The history of computer hardware dates back to the 1820s when Charles Babbage, an English mathematician, and inventor, designed the first analytical engine, which was considered to be the first mechanical computer. With time, more complex electronic computers were developed, including the first Intel microprocessor in 1971. Since then, computer hardware has continued to evolve, becoming

The Royal Pharmaceutical Society (RPS) has published its new 'Core Advanced Pharmacist Curriculum' to enable professional development towards advanced pharmacist practice. This follows an intensive programme of work undertaken in collaboration with a wide range of UK stakeholders, the society said today (June 27) in a statement. The Curriculum will equip pharmacists with advanced leadership, education, and research capabilities which are essential to support, lead and advance the profession through transformative change so it continues to meet evolving patient and service requirements. The RPS Core Advanced Curriculum provides the blueprint to develop such individuals by articulating a UK entry-level standard to advanced pharmacist practice, relevant to all patient-focussed pharmacist roles and aligned to multi-professional definitions of advanced practice. This curriculum completes the core RPS post-registration curricula, creating a seamless post-registration professional development continuum modelled around five common domains- Person-centred care and collaboration; Professional practice; Leadership and management; Education; and Research.

More than 10,000 pharmacy contractors those have declared their March FP34C submission figures through the Manage Your Service (MYS) portal by 5 April will receive earlier advance payments on Monday 11 April, the NHS Business Services Authority (NHSBSA) announced. Around 10,700 pharmacy contractors have made their submissions through MYS portal. They will receive their advance payments some 20 days earlier than the normal payment timetable. However, due to late submission (after April 5), over 500 contractors will not receive any earlier advance payments in April. These contractors will receive their advance payments on 1 May, in accordance with the normal payment timetable. From this month, MYS is the only route available to contractors for all monthly FP34C submissions. The Pharmaceutical Services Negotiating Committee (PSNC) reminded contractors that from this month (for prescriptions dispensed in March), the NHSBSA may apply an administrative deduction of £25 if a prescription bundle is submitted late.

More than 9,300 pharmacy contractors would benefit from earlier advance payment in February, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their January 2022 FP34C submission figures through the Manage Your Service (MYS) portal by February 5 will receive earlier advance payments by today (February 10). The statistics indicates nearly 2,000 contractors will not receive any earlier advance payment this month, either because their January declarations were submitted late or they used the paper FP34C submission document to make their declaration, PSNC said. These contractors will receive their advance payments in accordance with the normal payment timetable i.e. on March 1. The negotiator reminded contractors that from April 2022 MYS will be the only process to make monthly submissions.

The Royal Pharmaceutical Society (RPS) on Wednesday (14 February) launched consultations on two new pioneer curricula defining the clinical capabilities expected of entry-level advanced pharmacists practising in critical care and mental health. The advanced pharmacist critical care curriculum and the advanced pharmacist mental health curriculum are supplementary to the RPS core advanced curriculum. Interested stakeholders are invited to provide feedback on the content of the curricula, their feasibility in terms of delivery, their relevance to all countries, and how these may impact different social groups. Both consultations will be open until Tuesday 12 March, and members and non-members of RPS can submit their comments via the online form or the word document.

Move Free Total Joint Health - Advanced and MSM & nutriment D3 Description from Schiff, we're dedicated to finding the foremost effective ways that to assist individuals move higher and feel better. Move Free Advanced's formula takes Glucosamine/Chondroitin to future level by adding our advanced ingredients. So, it really helps improve your joint health.

Panadol launched a new purpose-led brand idea as part of a multi-channel campaign across Great Britain and Ireland. With nine out of 10 people suffering "everyday pain" and 65% of people saying they can't be happy when they are in pain[1], globally, the campaign reiterates the brand's commitment to holistic pain management by focusing on the acute pain recovery journey. Rooted in deep consumer understanding, the campaign idea celebrates that never-talked-about moment of realisation when you start to feel the release from pain. The new brand idea will bring to life the emotional transformation that those suffering from acute pain undergo, emphasising the role that Panadol can play in alleviating their pain. The Panadol campaign follows a period of strong sales growth for the brand, outperforming the category's own expansion by more than double[2]. This has been driven by shoppers who are searching for fast and effective pain relief products, such as Panadol's hero variants, including Panadol Extra Advance Tablets (paracetamol, caffeine), which has seen its growth almost doubled[3], as well as Panadol Advance Tablets (paracetamol) and Panadol Extra Advance Tablets. Monica Michalopoulou, GBI Marketing Director, said: "After two years of pandemic restrictions, now more than ever, people want to get back to their normal lives and to the people they love. But with pain preventing many of us from connecting with those we love or from doing the things we enjoy the most, we want to help consumers by understanding their pain journey and reassuring them on the treatments we can provide. This "Release" moment is so important for pain sufferers, and we hope our new brand campaign can shine a light on the role that Panadol can play in pain relief".

More than 6,000 pharmacy contractors who declared their October 2021 FP34C submission figures by November 5, will have received earlier advance payments on November 11. The contractors had submitted their claims through the Manage Your Service (MYS) portal. All contractors who received payments under the system would have got a letter from the NHS Business Services Authority (NHSBSA) regarding these payments,PSNC stated. Approximate 3,000 contractors submitted claims after November 5, and will receive payments as per the normal payment timetable on December 1, it said. The negotiator encouraged contractors to benefit from earlier advance payments by submitting their monthly declaration through the MYS portal by the 5th of the month.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

The Pharmaceutical Services Negotiating Committee (PSNC) has issued a revised guidance for the dispensing of controlled drugs in instalments on 19 September that has been declared as a bank holiday for Her Majesty The Queen's state funeral. PSNC said: "Many instalment prescriptions have already been issued in advance of the upcoming Bank Holiday. Where they contain the Home Office approved wording "Please dispense instalments due on pharmacy closed days on a prior suitable day" then you will need to plan to make these supplies at an appropriate time. This wording would also permit the supply of the initial dose of a prescription starting on the Bank Holiday Monday where the date of the signature is before this." However, PSNC is aware that not all prescriptions will contain such a direction to support the supply, in advance, of a dose for Monday 19 September where the supplying pharmacy is closed. "We recognise that this client group are often vulnerable with multi-morbidities and that the risk to them may be significant. You should therefore exercise your professional discretion in determining when to make an instalment supply for the Bank Holiday Monday. Make the care of the patient your first priority and consider the potential impact of both making the supply in advance and of not making the supply in your decision making process. The exceptional circumstances that led to the Bank Holiday and its short notice may inform your decision."

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer. "There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS," said NICE. The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment. Helen Knight, director of medicines evaluation at NICE, said: "Today's draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

Immunogenicity refers to the capacity of a vaccine to provoke an immune response in the body. An effective immune response is characterized by the production of specific antibodies, activation of immune cells, and the development of immunological memory. The goal is to elicit a durable and robust response that can prevent or control infections. Leveraging Viral Vector Technology Viral vectors serve as essential vehicles for delivering antigenic proteins or genetic material into target cells, triggering an immune response. Biotechnology companies have been exploring advanced strategies to optimize viral vector design, aiming to enhance immunogenicity and improve vaccine effectiveness. Vector Selection: The choice of viral vector plays a crucial role in determining immunogenicity. Different viruses have unique properties and characteristics that can impact immune responses. Biotechnology companies meticulously select viral vectors that possess the desired attributes, such as the ability to infect target cells efficiently and induce strong immune responses. Genetic Engineering: Advanced genetic engineering techniques are employed to modify viral vectors, tailoring them to specific vaccine requirements. By introducing specific antigenic proteins or genetic material, researchers can stimulate the immune system to mount a targeted response. This precise manipulation enhances the vaccine's ability to elicit a robust immune reaction. Immunomodulatory Elements: Biotechnology companies are incorporating immunomodulatory elements into viral vector designs. These elements can enhance the immune response by stimulating various components of the immune system, such as antigen-presenting cells and T cells. By activating and priming these immune cells, the vaccine can generate a more potent and sustained immune response. Adjuvants: Adjuvants are substances added to vaccines to enhance their immunogenicity. They stimulate and amplify the immune response, improving the va

Along with pharmacists, pharmacy technicians in England are now able to perform blood pressure checks as part of the Hypertension Case-Finding Service and deliver the Smoking Cessation Service (SCS). The government has amended Drug Tariff and includes the amendments to The Pharmaceutical Services (Advanced and Enhanced Services) (Amendment) (England) Directions 2023. Pharmaceutical Services Negotiating Committee (PSNC) said: "The service specifications for both services are currently going through NHS England's publication process; when these are published PSNC will alert contractors through their normal communication channels. PSNC resources for both of these services are also currently being updated."

Advanced eLearning Authoring Tools have made eLearning Development Easy The rapid and extensive advances in technology have brought on incredible innovation in all fields of human interest. The impact of the same can be seen in the e-learning space, and these days, this specialized segment is breaking new ground continuously.

Advanced eLearning Authoring Tools have made eLearning Development Easy The rapid and extensive advances in technology have brought on incredible innovation in all fields of human interest. The impact of the same can be seen in the e-learning space, and these days, this specialized segment is breaking new ground continuously.

500 hour yoga teacher training in Rishikesh at Hatha Yoga School in Rishikesh is designed to advance your yoga teacher training program, various yoga techniques, certified yoga instructor and yoga classes in Rishikesh. Yoga ttc in Rishikesh provides 100 hour, 200 hour, 300 hour, and 500 hour yoga teacher training in Rishikesh.

500 hour yoga teacher training in Rishikesh at Hatha Yoga School in Rishikesh is designed to advance your yoga teacher training program, various yoga techniques, certified yoga instructor and yoga classes in Rishikesh. Yoga ttc in Rishikesh provides 100 hour, 200 hour, 300 hour, and 500 hour yoga teacher training in Rishikesh.

Surgery is a field rife with innovation. New techniques, new technology, plus new ways of using existing techniques or technology, there's always something new brewing in regards to advancements in this sector.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.